Back to Registry

Ipamorelin

Also known as: NNC 26-0161, Ipamorelina, Ipamoreline

Investigational (IND)

Molecular Formula

C38 H49 N9 O5

Molecular Weight

711.85 Da

Half-Life

~2 hours

Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH2

Clinical Applications & Evidence

Mechanism of Action

Selectively binds to and activates the ghrelin/GHSR-1a receptor, leading to enhanced cyclic adenosine monophosphate (cAMP) production, increased protein kinase A (PKA) activation, stimulation of growth hormone-releasing hormone (GHRH) neurons, and direct pituitary somatotroph cell activation, triggering pulsatile GH release.

Investigated Uses

  • Growth hormone optimization
  • Body composition (lean mass / fat loss)
  • Bone density improvement
  • Post-operative recovery
  • Age-related muscle wasting
Moderate Clinical Data

Regulatory & Safety Status

FDA Status

Investigational (IND)

WADA / Athletic Status

Prohibited in Competition

Known Side Effects

HeadacheLightheadednessInjection site irritationTransient hunger increase

Contraindications

  • Active malignancy or history of hormone-sensitive cancers
  • Pregnancy and lactation
  • Uncontrolled diabetes mellitus
  • Pituitary adenomas or existing hypothalamic disorders

Drug Interactions

  • Often stacked with CJC-1295 for synergistic GH release
  • May interact with somatostatin analogs

Citations & Clinical Trials

PubMed Ipamorelin: The First Selective GH Secretagogue